Towards this direction, rapamycin, an inhibitor of mTOR, was shown to reduce α-synuclein accumulation in WT, A30P and A53T α-synuclein-overexpressing PC12 cells (Webb et al., 2003), to attenuate dopaminergic degeneration in neurotoxin-induced (Dehay et al., 2010; Malagelada et al., 2010; Liu et al., 2013) and α-synuclein-overexpressing PD models (Crews et al., 2010) and to improve motor function in A53T α-synuclein transgenic mice (Bai et al., 2015). Here, SNCA is linked to Parkinson disease.